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Abstract
Background:  Cellulose acetate phthalate (CAP), a pharmaceutical excipient used for enteric film
coating of capsules and tablets, was shown to inhibit infection by the human immunodeficiency virus
type 1 (HIV-1) and several herpesviruses. CAP formulations inactivated HIV-1, herpesvirus types 1
(HSV-1) and 2 (HSV-2) and the major nonviral sexually transmitted disease (STD) pathogens and
were effective in animal models for vaginal infection by HSV-2 and simian immunodeficiency virus.
Methods:  Enzyme-linked immunoassays and flow cytometry were used to demonstrate CAP
binding to HIV-1 and to define the binding site on the virus envelope.
Results:  1) CAP binds to HIV-1 virus particles and to the envelope glycoprotein gp120; 2) this
leads to blockade of the gp120 V3 loop and other gp120 sites resulting in diminished reactivity with
HIV-1 coreceptors CXCR4 and CCR5; 3) CAP binding to HIV-1 virions impairs their infectivity; 4)
these findings apply to both HIV-1 IIIB, an X4 virus, and HIV-1 BaL, an R5 virus.
Conclusions:  These results provide support for consideration of CAP as a topical microbicide of
choice for prevention of STDs, including HIV-1 infection.
Background
Due to the current unavailability of anti-HIV vaccines,
other preventive methods have to be developed to con-
trol the ongoing AIDS pandemic. This includes the de-
sign and application of safe and effective topical
microbicides. Screening of pharmaceutical excipients re-
vealed that cellulose acetate phthalate (CAP), commonly
used for enteric coating of tablets and capsules [1], has
anti-HIV-1 activity. CAP in micronized form and formu-
lated into a cream, is a broad spectrum microbicide inac-
tivating several sexually transmitted disease (STD)
pathogens [2–4], including HIV-1 [2,5]. It was of interest
to explore the mechanism(s) whereby CAP causes inacti-
vation of HIV-1. Since CAP has a relatively high molecu-
lar weight (Mw ~ 60,000; [2]), its effect on HIV-1 virions
would be expected to be confined to the virus surface, i.e.
to the envelope glycoproteins gp120 and/or gp41. Thus,
CAP would be expected to affect one or more steps re-
quired for HIV-1 entry into cells, i.e. binding to cellular
CD4, to the major HIV-1 coreceptors CXCR4 or CCR5 for
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X4 and R5 viruses [6], respectively, and fusion with cell
membranes [7–15]. Results presented here show that
CAP pretreated HIV-1 has a reduced capacity to bind to
the coreceptors leading to impaired virus infectivity.
Methods
Reagents
The following monoclonal antibodies (mAbs; the source
is indicated in parentheses) were used: 2F5 and 588D
(Drs. T. Muster and S. Zola-Pazner, respectively); 9305
and 9284 (NEN Research Products, Du Pont, Boston,
MA); b12, 2G12 and 17b (AIDS Research and Reference
Reagent Program, Rockville, MD; courtesy of Drs. D.
Burton, H. Katinger and J.E. Robinson, respectively) and
anti-p24 (ImmunoDiagnostics, Inc., Woburn, MA). Rab-
bit antibodies against peptides from HIV-1 IIIB gp120/
gp41 and against the V3 loop of HIV-1 BaL (anti-V3 BaL)
were prepared as described [16]. Antiserum to phthalate
was prepared by immunization of rabbits with phthalic
anhydride treated rabbit serum albumin [17]. Recom-
binant soluble CD4 (sCD4) was from Genentech Inc.,
South San Francisco, CA. Recombinant HIV-1 IIIB and
MN gp120, biotinylated gp120 and biotinylated sCD4
were from ImmunoDiagnostics Inc. Protein A, the pro-
tease inhibitors phenylmethyl-sulfonyl fluoride, leupep-
tin and pepstatin, and 2,3-bis [2-methoxy-4-nitro-5-
sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT)
were all from Sigma, St. Louis, MO. Pelletted, 1000-fold
concentrates of HIV-1 IIIB (6.8 ×  1010 virus particles/ml)
and BaL (1.8 ×  1010 virus particles/ml) were from Ad-
vanced Biotechnologies Inc., Columbia, MD. Chicken se-
rum was from OEM Concepts, Toms River, NJ.
Horseradish peroxidase (HRP)- and phycoerythrin (PE)-
labeled streptavidin were from Amersham, Arlington
Heights, IL and R & D Systems, Minneapolis, MN, re-
spectively. HRP was quantitated using a kit from Kirke-
gaard and Perry Laboratories Inc., Gaithersburg, MD.
Enzyme linked immunoassays (ELISA) kits for the HIV-
1 p24 antigen and for the β -gal protein were from Coulter
Immunology, Hialeah, FL and 5 Prime →  3 Prime Inc.,
Boulder, CO. CAP was a gift from Eastman, Kingsport,
TN. H9 cells chronically infected with HIV-1 IIIB, HeLa-
CD4-LTR-β -gal cells, GHOST CXCR4 and CCR5 cells
and PM1 cells were obtained from the AIDS Research
and Reference Reagent Program contributed by Drs. R.
Gallo, M. Emerman, D. Littman, P. Lusso and M. Reitz,
respectively. The Centricon centrifugal ultrafiltration de-
vices were from Amicon/Millipore, Bedford, MA.
Measurement of HIV-1 infectivity
Serial two-fold dilutions of CAP treated and untreated
HIV-1 IIIB (undiluted to 1/512) in RPMI-1640 medium
containing 10% fetal bovine serum (FBS) were mixed
with MT-2 cells (104 cells/well) and placed into 96-well
polystyrene plates. The mixtures were incubated for 1 h
at 37°C and the volume was adjusted with RPMI-1640
medium containing 10% FBS to 200 µl. On the 4th and
6th day after incubation at 37°C, 100 µl of culture super-
natants were removed from each well and equal volumes
of fresh medium were added. On the 6th day, XTT dye (1
mg/ml) was added to the cells, Intracellular formazan
was determined spectrophotometrically [18,19]. Similar
experiments were done with HIV-1 BaL, except that PM1
cells were used instead of MT-2 cells, and virus produc-
tion was measured by ELISA for p24 antigen one week
after infection. The percentage of residual infectivity af-
ter CAP treatment was calculated from calibration curves
relating absorbance (corresponding to formazan for
HIV-1 IIIB and p24 antigen for HIV-1 BaL, respectively)
to virus dilutions of untreated viruses. The results were
plotted in Fig. 1.
Enzyme-linked immunosorbent assays (ELISA)
For virus capture assays, wells of 96-well polystyrene
plates (Immulon II; Dynatech Laboratories Inc., Chant-
illy, VA) were coated either with sCD4 (1 µg/well) or with
monoclonal or polyclonal antibodies. For coating with
antibodies, wells were first coated with protein A (1 µg/
well) in 0.1 M Tris buffer, pH 8.8 for 2 h at 20°C followed
by either mAbs (1 µg/well) or rabbit antisera diluted
1:100 in phosphate buffered saline (PBS) for 1 h at 20°C.
Subsequently, the wells were washed and postcoated for
1 h at 20°C with bovine serum albumin (BSA) and gelatin
(1 and 0.1 mg/ml in 0.14 M NaCI, 0.01 M Tris, pH 7.0
[TS]). Chicken serum (10%) in PBS (Ch-PBS) was used
instead in experiments with HIV-1 BaL. The wells were
washed with TS and stored at 4°C. HIV-1 virus particles
suspended in PBS were added to the wells for 5 h at 4°C.
Subsequently, the wells were washed 10 ×  with ice cold
PBS or 1:50 anti-p24 mAb in Ch-PBS for HIV-1 BaL, and
then treated with lysis buffer (1% Nonidet P40 [NP40],
100 µg/ml BSA in PBS) for 30 min at 37°C. The superna-
tants were removed and tested for p24 antigen using
ELISA kits from Coulter Immunology and following the
manufacturer's protocol. In other experiments, wells
were coated with CAP (1 µg/ml) in 25 mM sodium ace-
tate, pH 6.0 and postcoated as described above.
To detect binding of CD4 to CAP treated and control
gp120, wells coated with graded amounts of gp120 and
postcoated as described above were reacted with bioti-
nylated sCD4 (1 µg/well) in PBS containing 100 µg/ml
BSA for 18 h at 4°C, washed with TS and the bound bioti-
nylated CD4 was determined after adding HRP-strepta-
vidin (1 µg/ml) in TS containing 0.25% gelatine and
0.05% Tween 20 for 30 min at 37°C. The wells were
washed and bound HRP was detected using the test kit
from Kirkegaard and Perry and the absorbance read at
450 nm.BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
Flow cytometry
To determine the binding of gp120–biotinylated CD4
complexes to HIV-1 coreceptor expressing cells, CAP
treated and untreated gp120 (5 µg) and biotinylated CD4
(2.5 µg) in PBS containing 100 µg/ml of BSA were mixed
for 1 h at 20°C and then added to 106 MT-2 cells in
RPMI-1640 medium containing 100 µg/ml of BSA. Bioti-
nylated CD4–gp120 complexes were not added to con-
trol cells. After 30 min at room temperature, the cells
were washed 3 times with PBS containing 100 µg/ml of
BSA, and PE-streptavidin (0.1 µg) was added. After 20
min at 20°C, cells were washed and fixed in 1% formalde-
hyde in PBS. Flow cytometry analysis was performed in
a FACSCalibur flow cytometer (Becton Dickinson Immu-
nocytometric Systems, San Jose, CA). Similar experi-
ments were done with peripheral blood lymphocytes
(PBL) isolated by the Isopaque-Ficoll technique [20].
Quantitation of CAP–gp120 binding
Forty µg of gp120 were mixed with 40 µg of CAP in 1 ml
TS or 1 M NaCI, 0.01 M Tris, pH 7.0 and incubated at
20°C for 30 min. The mixtures were transferred into a
Centricon centrifugal ultrafiltration device with a Mw
cut-off of 100,000 and centrifuged at 3,500 ×  g for 30
min. The filtrates were transferred to a similar device
with a Mw cut-off of 50,000 and centrifuged under the
same conditions. CAP retained on top of the filter was
quantitated as a complex with ruthenium red [21]. The
retentate on the 100,000 Mw cut-off filter was dissolved
in 1 ml of 2 M guanidinium hydrochloride and CAP re-
leased from the CAP–gp120 complex and retained on the
50,000 Mw cut-off filter was quantitated by the same
method.
Molecular Modeling
A cellulose chain consisting of one cellotetraose unit
(composed of four 1,4-linked β -D-glucose units) was cre-
ated in Quanta [22] and 50% of the hydroxyl groups at
positions 2- and 3- were modified to acetyl ester and 25%
of the hydroxyl groups at position 6 were modified to
phthaloyl ester [1,23]. The acetylated and phthaloylated
cellotetraose structure (CTAP) was minimized by the
steepest descent method followed by the adopted basis
Newton-Raphson (ABNR) method. The energy change of
0.05 Kcal/mol between two successive structures was
used as the termination criterion in both the steps.
The crystal structure of gp120 (1gcl) [13] was retrieved
from the pdb ( [http://www.rcsb.org] ) and the V3 loop,
created by homology modeling {(based on the nmr struc-
ture of the V3 loop from 1ce4) using the SWISS-MODEL
[24] automated comparative protein modeling server (
[http://www.expasy.ch/SWISS-MODEL.html] } was at-
tached to the gp120 crystal structure using Quanta's pro-
tein design module.
The docking simulation of CTAP onto the entire gp120
protein surface was performed by the Dockvision pro-
gram [25]. A grid box (125 Å ×  125 Å ×  125 Å) with grid
stepsize of 0.5 Å was created to cover the entire protein
surface with enough area for the ligand to dock. The de-
fault forcefield (Research Potential Function) was used
to perform 1000 Monte Carlo runs for the docking. Both
ligand and the target protein were kept rigid. Intermo-
lecular energy criteria were used to identify the best pos-
sible dockings of CTAP.
Results
Impaired infectivity of CAP treated HIV-1
Results of earlier studies indicated that HIV-1 infection
of cells is inhibited in the presence of CAP (ED90 = 5 to
10 µg/ml for HIV-1 IIIB, i.e. < 200 nM) [2]. However, the
mechanism involved in the inhibitory activity and the
possibility of virus inactivation by CAP have not been ex-
plored. Results shown in Fig. 1 indicate that CAP in a
dose dependent manner rapidly inactivates at 37°C HIV-
1 IIIB, an X4 virus and HIV-1 BaL, an R5 virus, the latter
appearing relatively more resistant.
CAP retention on the surface of treated HIV-1 particles
Evidence for CAP–HIV-1 binding was obtained from re-
sults of solid phase immunoassays in which attachment
of HIV-1 IIIB and BaL virus particles, respectively (de-
tected by subsequent ELISA of p24 antigen released
from virus particles by detergent treatment) to wells pre-
coated with CAP was measured (Fig. 2A). CAP treated
HIV-1 IIIB and BaL viruses, unlike control viruses,
bound to wells coated with antibodies against phthalate
(Fig. 2B). These results indicate that treated HIV-1 parti-
cles, utilizing either CXCR4 or CCR5 as coreceptors, re-
tain CAP on their surface and suggest that this is
responsible for the altered properties and impaired in-
fectivity of the treated viruses.
Identification of CAP binding sites on HIV-1 envelope glyc-
oproteins
The attachment sites on the surface of HIV-1 IIIB for
CAP were determined from binding of control and CAP
treated HIV-1, respectively, to distinct ligands (Fig. 3).
The quantities of control virus and treated virus in these
experiments were identical, as determined from the con-
tent of p24 antigen in preparations of detergent-disrupt-
ed virus particles. CAP binding to HIV-1 IIIB particles
most profoundly affected their binding to the V3 loop
specific mAbs 9284 [26] and 9305 [27] and to the core-
ceptor CXCR4, while binding to sCD4; to virus neutraliz-
ing mAbs specific for the CD4 binding site on gp120, b12
[28] and 588D [29]; to mAb 17b specific for a discontin-
uous conserved epitope proximal to the binding site for
both CD4 and anti-CD4 binding site antibodies [30]; to
mAb 2G12 specific for an epitope centered around theBMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
C3/V4 domain of gp120 also involving N-linked glycans
[31] and to the gp41 specific mAb 2F5 [32] was less af-
fected. In order to determine whether R5 viruses are sim-
ilarly affected by CAP, the binding of HIV-1 BaL as a
representative of this virus group to anti-V3 BaL and
CCR5, respectively, before and after CAP treatment was
studied. The results shown in Fig. 3 indicate that the
CAP-treated HIV-1 BaL bound to these ligands much less
than did untreated virus.
The binding of control and CAP-treated HIV-1 IIIB to an-
tibodies against peptides derived from gp120/gp41 [16]
was also determined. In agreement with the results ob-
tained using mAbs, CAP treatment resulted in most pro-
nounced decreases of virus binding to antibodies against
peptide 303–338 (= V3 loop) and the adjacent peptide
280–306 (Fig. 4).
Pretreatment with CAP impairs gp120 binding to corecep-
tors
Data reported so far suggest that the lethal hit to HIV-1
caused by CAP treatment involves the coreceptor bind-
ing site on gp120. To further support this conclusion, the
binding of labeled gp120–CD4 complexes to coreceptor
[11,12,33] expressing cells was studied. First, it was de-
termined from quantitative binding studies using CAP
Figure 1
Inactivation of HIV-1 by CAP. Cellulose acetate phthalate (CAP) (final concentrations between 10 and 0.078 mg/ml) was added
to HIV-1 IIIB containing tissue culture medium and to HIV-1 BaL, respectively. After incubation for 5 min at 37°C, the mixtures
were cooled on ice and a solution of polyethylene glycol 6000 (PEG) [Reference 53] was added to a final concentration of 3%
to separate HIV-1 from CAP (which does not precipitate in 3% PEG). After 90 min at 4°C, the mixtures were centrifuged at
10,000 rpm, the supernatant fluids removed and the pellets washed twice with 3% PEG in PBS containing 10 mg/ml BSA. The
final pellets were resuspended in tissue culture medium and titered for infectivity. The percentage of residual infectivity is
shown in a probability scale.BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
Figure 2
Evidence for CAP binding to HIV-1 virus particles. A) Virus binding to CAP coated wells. B) Binding of CAP treated and
untreated HIV-1 IIIB and BaL, respectively, to wells coated with antibodies against phthalate [reference 17]. CAP was added to
a final concentration of 5 mg/ml to 50 µl of suspensions of purified HIV-1 IIIB (6.8 ×  109 virus particles per ml) and HIV-1 BaL
(1.8 ×  1010 virus particles per ml), respectively, in 0.1 M sodium acetate pH 7.0. CAP was not added to control virus prepara-
tions. After 5 min at 37°C, HIV-1 was separated from unbound CAP as described for Fig. 1. The pellets containing HIV-1 were
resuspended in 50 µl PBS containing 100 µg/ml BSA. 200 µl of 5-fold diluted virus supensions containing equal amounts of virus
particles for both CAP treated and control virus (as determined by quantitation of p24 antigen), were added to wells coated as
indicated above and to control wells. Bound virus was quantitated by ELISA for p24 antigen.BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
staining with ruthenium red [21] that pretreatment with
CAP resulted in binding of 0.90 ± 0.13 CAP molecules/
gp120 in TS. The binding appeared augmented by ~ 30%
in 1 M NaCl. The binding capacity of gp120 for sCD4 was
preserved after CAP treatment (Fig. 5). On the other
hand, gp120–sCD4 complexes containing CAP treated
gp120 bound to coreceptor expressing cells to a much
lesser extent than similar complexes containing untreat-
ed gp120 (Fig. 6).
Discussion
Negatively charged sulfated polymers were reported to
have anti-HIV-1 activity and are being considered for de-
velopment as topical microbicides. They include: dex-
Figure 3
Binding of CAP treated and untreated HIV-1 to distinct ligands. The binding of untreated and CAP treated HIV-1 IIIB to wells
coated with sCD4 or with distinct mAbs and of HIV-1 BaL to anti-V3 BaL was measured as described for Fig. 2. The % of bind-
ing corresponding to CAP treated virus was calculated based on the formula (% residual binding = [absorbance corresponding
to bound CAP treated virus ÷ absorbance corresponding to bound untreated HIV-1] ×  100. Absorbance corresponding to p24
antigen (5-fold dilution of the sample) from untreated HIV-1 bound to the respective ligands was in the range of 0.56 to 1.54.
Absorbance corresponding to virus captured onto wells coated with control IgG was 0.046. All experiments were done in trip-
licate. To measure virus binding to the coreceptor CXCR4, treated and control HIV-1 IIIB recovered after PEG precipitation
was mixed with 10 µg of sCD4. After 5 min at 20°C, the respective samples were divided into 2 aliquots, each of which was
added to 5 ×  105 GHOST CXCR4 cells suspended in 100 µl PBS containing 100 µg/ml of BSA. Similar experiments were car-
ried out with purified HIV-1 BaL, except that GHOST CCR5 cells were used. After 1 h at 4°C, the cells were pelletted and
washed with ice cold PBS containing 100 µg/ml BSA. The pelletted cells were lysed for 30 min at 37°C in PBS with 1% NP40.
Serial 5-fold dilutions in PBS (1:5 to 1:4.9 ×  107) were tested by ELISA for the p24 antigen. Changes in HIV-1 binding were
determined using calibration curves relating absorbance to virus dilutions.BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
tran sulfate [34,35], carrageenans [35,36], dextrin-2-
sulfate [37,38], cellulose sulfate [39] and naphthalene
sulfonate polymer (PRO 2000; [40]). Except for dextrin-
2-sulfate and PRO 2000, which appear to have anti-HIV-
1 inhibitory activities similar to that of CAP, the other
sulfonated polymers are less inhibitory [34,35,41]. HIV-
1 may develop resistance to the inhibitory effect of dex-
tran sulfate and R5 viruses were reported not to be inhib-
ited by this polymer [42,43]. Dextran sulfate was shown
to bind to gp120 and to interfere with gp120/CXCR4 in-
teractions but it did not bind to gp120 of R5 viruses [43].
CAP in micronized form, providing an acidic environ-
ment, causes disintegration of HIV-1 leading to loss of
infectivity (2). Here we have shown that CAP directly in-
activates HIV-1 at neutral pH since treated virus parti-
cles after removal of excess CAP had reduced or no
infectivity (Fig. 1), in agreement with recent observations
[44,45]. Virus inactivation can be attributed to strong
binding of CAP to HIV-1, preventing the access to virus
particles predominantly of antibodies against the gp120
V3 loop, known to be involved in coreceptor binding and
specificity [15,46–49], and to epitopes located adjacent
to the V3 loop (Fig. 4). Indeed, CAP binding to HIV-1 re-
sulted in blockade of sites involved in coreceptor binding
(Fig. 3). This was observed for both HIV-1 IIIB, an X4 vi-
rus, and HIV-1 BaL, an R5 virus. In agreement with this
finding, CAP inhibited infection by both X4 and R5 vi-
ruses in in vitro models for vaginal HIV-1 infection
[45,50]. Sites on the HIV-1 envelope other than the core-
Figure 4
Binding of CAP treated and untreated HIV-1 IIIB to wells coated with antibodies to peptides from gp120/gp41 [reference 16].
Experimental conditions were similar to those described in the legend for Fig. 3. The absorbance corresponding to untreated
HIV-1 captured onto the wells was in the range of 0.09 to 0.37. The absorbance corresponding to controls (virus captured
onto wells coated with Protein A followed by normal rabbit serum) was 0.014. Numbering of gp160 amino acid residues was
the same as in reference 16. Decreases of CAP treated virus binding, as compared with binding of control virus, were plotted.BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
ceptor binding domains may possibly be also involved in
interactions with CAP, contributing to inhibition of virus
infection.
Studies with gp120 allowed to determine the stoichiom-
etry of the reaction between gp120 and CAP, resulting in
the observation that approximately one CAP molecule
binds to one molecule of gp120. Interestingly, CAP–
gp120 binding also occurs in 1M NaCl, conditions under
which binding of sulfated polysaccharides to gp120 is
abolished [43]. This suggests that electrostatic interac-
tions do not play an exclusive role in CAP–gp120 binding
[51].
Since CAP has an approximate Mw of 6 ×  104 and its
structure has not been determined, a model for CAP
docking onto gp120 (HXBc2) was generated using a
chemically modified cellotetraose. The entire gp120 sur-
face was considered for docking acetylated and
phthaloylated cellotetraose (CTAP) except the trimeriza-
tion and CD4 binding sites on gp120 [13]. The two opti-
mally docked CTAP molecules were selected for further
analyses. The first one (marked as Dock1 in Fig. 7)
docked near regions corresponding to amino acid resi-
dues 361–392 (indicated in red) and 386–417 (indicated
in purple). The orientation of CTAP revealed that if ex-
tended to generate the larger CAP molecule, blockade of
the coreceptor binding site (indicated in gray in Fig. 7)
Figure 5
Binding of sCD4 to CAP treated and untreated gp120. Recombinant gp120 IIIB (5 µg in 400 µl of 0.1 M sodium acetate buffer
pH 7.0) was treated with CAP (5 mg/ml) for 5 min at 37°C and then cooled to 0°C. CAP was omitted in control experiments.
BSA was added to a final concentration of 25 µg/ml and the samples were filtered using a 2 ml Centricon centrifugal ultrafiltra-
tion device with a Mw cutoff of 100,000 and centrifuged at 3,500 ×  g for 30 min. gp120 retained on the filters was washed with
PBS, resuspended in PBS, and serially diluted 5-fold. The diluted samples (corresponding to gp120 quantities indicated on the
abscissa) were used to coat wells of 96-well polystyrene plates. Binding to the wells of biotin labeled sCD4 was detected from
subsequent binding of HRP-streptavidin.BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
Figure 6
Binding of sCD4 complexes with CAP treated and control gp120, respectively, to HIV-1 coreceptor expressing cells. CAP
treated or control gp120 IIIB or MN (prepared as described for Fig. 5) were mixed with biotinylated sCD4 and added to 106
MT-2 cells (A) or PBL (B and C). The cells were washed with PBS, treated with phycoerythrin (PE)-labeled streptavidin, fixed in
1% formaldehyde and submitted to flow cytometry analysis.BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
[15] and the V3 loop (indicated in yellow in Fig. 7) would
result. These docking results agree with the observation
that capture of CAP treated HIV-1 virions to antibodies
against peptides from these regions (303–338, 361–392,
386–417) was decreased (Fig. 4). CTAP interacts prima-
rily through several hydrogen bonds with gp120 residues
K362, N386, Q389, N392 and T394. Though there were
no hydrophobic or electrostatic interactions discernable,
such interactions cannot be ruled out as CTAP represents
only a small part of the CAP molecule. The second best
docking positioned CTAP near the V3 loop (marked as
Dock2 in Fig. 7). CTAP in this position interacts with
gp120 through both hydrogen bonding (residues R311
and R315) and hydrophobic forces (F317) with two
CH3CO- units of CTAP. The interacting region is in the
RGPGRAF principal neutralizing domain (PND) of the
V3 loop [52]. Both R311 and R315 residues are also in
close proximity to two acid groups of the CTAP phthalic
acid moiety and may take part in electrostatic interac-
tions. Although CTAP is only a partial representation of
the CAP molecule, the docking simulations agree with
the experimental results.
Results presented earlier [2] combined with those pre-
sented here suggest that CAP acts on HIV-1 by several
mechanisms, depending on pH and the physical form
Figure 7
Stereodiagram of two best docked modified cellotetraose units (CTAP) (marked as Dock1 and Dock2, respectively) on the x-
ray crystal structure of gp120 (HXBc2 strain) with the V3 loop attached. The residues on gp120 nearest to the docked CTAPs
are shown to indicate possible interaction patterns. The V3 loop (peptide 303–338) is indicated in yellow. Regions correspond-
ing to peptides 113–142, 280–306, 361–392 and 393–417 (Fig. 4) are indicated in orange, green, red and purple, respectively.
The coreceptor binding site is indicated in gray. The rest of the gp120 is in cyan. The figure was generated using the Sybyl pro-
gram [54].BMC Infectious Diseases 2001, 1:17 http://www.biomedcentral.com/1471-2334/1/17
and concentration of this compound. The direct virus in-
activating effect of CAP, the multiple mechanisms in-
volved in prevention of HIV-1 infection, the broad
spectrum activity against several STD pathogens, the es-
tablished safety record, low cost and availability in large
scale suggest that CAP has advantages over other poly-
meric substances considered as topical (vaginal) micro-
bicides for prevention of STDs, including AIDS.
Conclusions
Cellulose acetate phthalate (CAP) is a pharmaceutical ex-
cipient which has been used for over four decades for en-
teric film coating of tablets and capsules. It is
inexpensive and generally regarded as a nontoxic mate-
rial free of adverse effects. As such, it is included in the
US Food and Drug Administration Inactive Ingredients
Guide. Our earlier studies indicated that CAP inhibited
infection by HIV-1 and several herpes viruses in vitro.
CAP was effective in blocking vaginal transmission of
these viruses in animal model systems. The underlying
molecular machanisms for these inhibitory effects re-
mained to be established. Data presented here show that
CAP remains bound to HIV-1 after removal of unreacted
compound, impairing virus infectivity due to blockade of
binding sites for cellular coreceptors CXCR4 and CCR5.
The industrial availability, history of safe use and mech-
anism of anti-HIV-1 activity (i.e. virus inactivation rather
than reversible inhibition) suggest that CAP is an ideal
candidate compound for a vaginal microbicide expected
to prevent sexual transmission of HIV-1.
List of Abbreviations used
CAP, cellulose acetate phthalate; STD, sexually transmit-
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